Cover Story
By Matthew Bin Han Ong
A federal judge has ruled against the Health Resources and Services Administration over provider access to 340B Drug Pricing Program discounts for orphan drugs.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- Moving from mandate to mission: Community outreach and engagement at NCI-designated cancer centers
“COE is broken.” - Don’t confirm RFK Jr. for HHS, 77 Nobel laureates urge the Senate
- Trump 2016: A look back at the 45th president’s impact on oncology
- Art exhibit at University of Miami Sylvester bridges North and South America
- VCU awarded $9M from NCI to establish Cancer Control Equity Research Center
- The Cancer Letter’s most-read stories of 2024